Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01EO0901)
Article History
Received: 25 October 2018
Revised: 27 November 2018
Accepted: 8 December 2018
First Online: 13 December 2018
Compliance with ethical standards
:
: M. Strupp is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speaker’s honoraria from Abbott, Actelion, Auris Medical, Bayer, Biogen, Eisai, Grünenthal, GSK, Henning Pharma, Interacoustics, Merck, MSD, Otometrics, Pierre-Fabre, TEVA, and UCB. He is a shareholder of IntraBio. He acts as a consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion. O. Bayer and K. Feil report no relevant conflicts of interest/financial disclosures. A. Straube has received speaker’s honoraria from Allergan, Novartis, TEVA and Recordati. He received honoraria for adboard participation from Allergan, Novartis, TEVA, Eli Lilly, electroCore.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: All patients gave their informed consent for the compassionate use of acetyl-<scp>dl</scp>-leucine.